

USSN 09/881,126

Amended Claims

- B<sup>1</sup>
1. Cancelled
  - 5 2. Cancelled
  3. Cancelled
  - 10 4. Cancelled
  5. Cancelled
  6. Cancelled
  - 15 7. Cancelled
  8. Cancelled
  - 20 9. Cancelled
  10. Cancelled
  11. Cancelled
  - 25 12. Cancelled
  13. Cancelled
  - 30 14. Cancelled
  15. Cancelled
  16. Cancelled
  - 35 17. Cancelled
  18. Cancelled
  19. Cancelled
  - 40 20. Cancelled
  21. Cancelled
  - 45 22. Cancelled
  23. Cancelled

60,800A

24

USSN 09/881,126

24. Cancelled

25. Cancelled

5 26. Cancelled

27. Cancelled

10 28. Cancelled

29. Cancelled

30. Cancelled

15 31. Cancelled

32. (Original) A method for treatment of cancerous tumors in mammals, comprising administering a therapeutically effective quantity of a dendritic polymer-platinate compound to a mammal having a cancerous tumor.

20

33. (Original) The method of claim 32, wherein the dendritic polymer is a dendrimer.

34. (Original) The method of claim 32, wherein the dendritic polymer has anionic functional groups.

25

35. (Original) The method of claim 34, wherein the anionic groups are carboxylate groups.

30 36. (Original) The method of claim 32, wherein the dendritic polymer is a polyamidoamine dendrimer.

37. (Withdrawn) The method of claim 32, wherein the dendritic polymer is polypropylamine.

35 38. (Original) The method of claim 32, wherein the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands

USSN 09/881,126

being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

39. (Original) The method of claim 32, wherein the platinum containing compound is  
5 cisplatin.

40. (Withdrawn) The method of claim 32, wherein the dendritic polymer-platinate  
compound is administered parentally.

41. (Original) The method of claim 32, wherein the dendritic polymer-platinate  
10 compound is administered intravenously or intraperitoneally.

42. (Withdrawn) The method of claim 32, wherein the dendritic polymer-platinate  
compound is administered orally.

43. (Withdrawn) The method of claim 32, wherein the dendritic polymer-platinate  
15 compound is administered topically.

44. (Original) The method of claim 32, wherein the dendritic polymer-platinate  
20 compound is administered intraperitoneally.

45. (Original) The method of claim 32, wherein the molar ratio of cisplatin to  
dendritic polymer in the conjugate is from about 100:1 to about 1:1.

25 46. (Original) The method of claim 32, wherein the molar ratio of cisplatin to  
dendritic polymer in the conjugate is about 35:1.